Observational studyMedicine2020

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.

Saara Huoponen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.